[Bradycardia after beginning therapy with metoprolol and paroxetine].
Because of their low incidence of adverse effects SSRI are prescribed more and more frequently in patients with depressive disorders. SSRI inhibit different subsystems of cytochrome-P 450-oxydase. Especially during co-administration of SSRI with antipsychotic and antiarrhythmic drugs pharmacokinetic interactions have to be observed carefully. In this presentation a case of bradycardia after co-administration of paroxetine and metoprolol is reported. Drug history and a careful drug monitoring are necessary requirements to avoid serious adverse effects.
König
F
F
Abteilung Psychiatrie I, Universität Ulm, Ravensburg.
Häfele
M
M
Hauger
B
B
Löble
M
M
Wössner
S
S
Wolfersdorf
M
M
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D001919:Bradycardia / Q000139:chemically induced* / Q000175:diagnosis; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D016651:Lithium Carbonate / Q000008:administration & dosage / Q000009:adverse effects; D008790:Metoprolol / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects*
D000319:Adrenergic beta-Antagonists; D018687:Antidepressive Agents, Second-Generation; D016651:Lithium Carbonate; D017374:Paroxetine; D008790:Metoprolol